MENUCLOSE

 

Connect with us

Meeting the ArcheMedX Team at SCOPE 2022

by ArcheMedX Team Jan 27 , 2022 2 min read

How can you minimize the performance risks given the complexities of a clinical trial and be ready to effectively conduct your next study?

As we prepare to attend the annual SCOPE Summit of Clinical Operations Executives in Orlando, FL, February 7 – 10, the rise in decentralized trials (DCTs) and increased study complexity have not gone unnoticed.  

For CROs and PIs, preparing sites and decentralized teams in a timely, effectively trained, and measurable manner has become a mission critical and increasingly difficult task.

As a result, of the roughly 401,898 globally registered clinical studies currently in process, more than 90% will miss key milestones and thousands will ultimately fail to meet primary endpoints due to operational complexity and costly delays that could have been mitigated and prevented sooner.

Join the ArcheMedX team at SCOPE (in booth 220 – next to Medable) and discover Ready, the only clinical trial team learning and analytics platform, that reveals which sites and decentralized teams are best prepared to successfully conduct the most critical aspects of a study – and dynamically upskills those in need.

Learn how you can overcome the complexity in your next traditional or decentralized study by predicting and improving the performance of your trial team.

Visit us at Booth #220 @ #SCOPE2022 and request a demo today.

Related Post

12 min Read 27 Jun, 2025

Reflections from DIA and BIO: What Trial Leaders Are Really Saying

I. Introduction: Two Conferences, One Reality This past week at DIA and BIO offered two…

7 min Read 23 Jun, 2025

What We Think We Know: How Overconfidence Derails Clinical Trials

In clinical research, where accuracy, coordination, and compliance are non-negotiable, the greatest threat isn’t always…

Brian S McGowan, PhD
Brian S McGowan, PhD
7 min Read 8 Jun, 2025

Why Mindset Matters in Clinical Research

Clinical trials professionals face a host of challenges: for some, it’s the complexity in protocol…

Brian S McGowan, PhD
Brian S McGowan, PhD